Chugai Seiyaku Kabushiki Kaisha

Osamu Cynshi

Yoshiaki Kato

Kunio Tamura

Yasuhiro Ohba

Mitsutaka Yoshida

Akira Ishikawa

Yoshiaki Takashima

Reiko Sekimori

Hideki Sato

Koji Mizuno

Hisanori Takanashi

Tatsuhiko Iwase

Kenshi Kamei

Hirokazu Sudo

Kenichi Ozaki

The present invention provides a therapeutic and/or preventive agent against gastroparesis symptom which is appropriate for continuous medication and which comprises a compound represented by formula (1): (wherein Rrepresents a C-Calkyl group and Rrepresents a C-Calkyl group) or a pharmaceutically acceptable salt thereof as an active ingredient. The erythromycin derivative of the formula (1) has an efficacy of improving gastroparesis and this action of the derivative in improving gastroparesis symptom is not found in ABT-229, a different motilin agonist erythromycin derivative. Further, the compound of the formula (1) is also appropriate for long-term clinical use because of its much weaker antibacterial action than that of erythromycin. Accordingly, the present invention provides a pharmaceutical agent that is safe and exhibits potent therapeutic and/or preventive effect in an effort to improve symptomatic gastroparesis.

Drugs for the treatment and/or prophylaxis of gastroparesis symptom

A compound of Formula (1) or a pharmaceutically acceptable salt thereof: wherein Rrepresents a C-Calkyl group and Rrepresents a C-Calkyl group, while unlike a laxative, is effective in the treatment of constipation.

Methods of treating dyschezia

2,3-dihydrobenzofuran derivatives

Intimal thickening inhibitory agent

Prophylactic/therapeutic agents for atherosclerosis

Therapeutic agents for renal diseases and organ preservatives

Compounds represented by the general formula (I), as well as intermediates for the synthesis of thereof: ##STR1## where R.sup.1 is a hydrogen atom or an acyl group; R.sup.2 is a lower alkyl group; R.sup.3 is a hydrogen atom or a lower alkyl group; R.sup.4, R.sup.5 and R.sup.6, which may be the same or different, are a hydrogen atom or an optionally substituted alkyl, alkenyl, alkynyl or aryl group; R.sup.2 and R.sup.4, when taken together, may form a 5-membered ring; R.sup.5 and R.sup.6, when taken together, may form a cycloalkyl group or a heterocyclic group in which at least one methylene on the ring of a cycloalkyl group is substituted by an oxygen atom, a sulfur atom or an alkyl-substituted nitrogen atom, provided that R.sup.6 is not present if the ring formed by R.sup.2 and R.sup.4 taken together is a benzofuran ring. The compounds represented by the general formula (I) have a highly selective anti-oxidative activity and are useful as therapeutics of ischemic diseases such as arteriosclerosis and myocardial infarction.

4-alkoxy-2, 6-di-t-butylphenol derivatives

4,6-Di-t-butyl-dihydrobenzofuran-5-ol and its derivatives

A pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis comprising a therapeutically effective amount of human erythropoietin (EPO) in a parenterally acceptable vehicle is disclosed. Human EPO may be extracted from human urine or also be prepared by expressing in a host cell the gene coding for the amino acid sequence of human EPO.

Pharmaceutical composition for the treatment of the anemia of rheumatoid

Growing community of inventors

Shizuoka-ken, Japan

Osamu Cynshi